Oscotec Inc.

Notice Press Releases Publications IR Materials

List of Articles
Date	Site	Media	Pipeline
2019-01-28	Genosco gears up for IPO	THE INVESTOR	Genosco
2018-11-23	Oscotec`s acute leukemia treatment wins orphan drug status from FDA	KBR (; Korea Biomedical Review)	SKI-G-801
2018-11-05	Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech	BusinessKorea	Lazertinib
2018-06-11	Yuhan ups investment in biotechs for immuno-oncology drug push	THE INVESTOR	Yuhan/Lazertinib
2018-06-03	"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"	Businesswire	Lazertinib
2018-05-16	Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018	Businesswire	Lazertinib
2018-03-14	More than half of Korean biopharma firms view R&D investments as assets.	The Korea Herald	Industry
2017-12-11	Oscotec shares rebound on launch of US clinical trial	KBR (; Korea Biomedical Review)	SKI-G-801
2016-08-23	INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs	Scrip (Informa Pharma Intelligence)	Oscotec
2016-01-19	Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money	Scrip (Informa Pharma Intelligence)	SYK-O-703
2014-04-03	G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.	PubMed	SKI-G-801
2007-02-19	Profiles of Four New Stock-Billionaires	MBN	Oscotec

To inquire